
Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK
Description
About Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK
The Respiratory Syncytial Virus (RSV) Fusion glycoprotein F0 Peptide (IEDB: 99766) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Fusion glycoprotein F0 Peptide, H-VQLPLYGVIDTPCWK-OH (Uniprot: O09635 aa: 299-312) from JPT is produced under strict quality control and quality management.
Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK - Specifications
- Peptide sequence: H-VQLPLYGVIDTPCWK-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK
References:
Read References with JPT’s Antigen Peptides
Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK has been described in:
Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes., J Virol, 1991 (PMID: 1710289)
Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection., J Clin Invest, 2020 (PMID: 31815739)
Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19., Nat Immunol, 2020 (PMID: 32887977)
Documentation
Documentation for Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK
Properties
Properties of Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Respiratory Syncytial Virus (RSV) |
Protein Name: | Fusion glycoprotein F0 |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human RSV Fusion glycoprotein F0 299-312, VQLPLYGVIDTPCWK
Information | Values |
---|---|
Sequence: | H-VQLPLYGVIDTPCWK-OH |
Specifications: | 15mer peptide as TFA salt |